Table 2.
Overview of clinical trials registered on clinicaltrials.gov; accessed on 20 January 2021 investigating a potential benefit of MSCs in HSCT in neuroblastoma.
| Phase | Details | Properties and Median Dose of MSCs | Nr. of Patients | Disease Context | Key Findings | Publication/Status | ClinicalTrials.gov Identifier | Year | |
|---|---|---|---|---|---|---|---|---|---|
| allo-MSCs | |||||||||
| A | I | Allogeneic MSCs co-transplanted with haplo-HSCT and subsequent DLI | Allogeneic BM-MSCs, 0.75 × 106 MSC/kg | n = 5 (all received MSCs, no control) | NB (relapsed/refractory) | 2 of 5 patients achieved long-lasting remission (40 and 42 months) | Toporski et al. [82] | NCT00790413 | 2008 |
| Neutrophil recovery in all children (median 13 days), platelet recovery in 4/5 children (12 days) | |||||||||
| Rapid immune reconstitution of NK- and T cells | |||||||||
| No primary aGVHD, but 4/4 patients had secondary GvHD after DLI | |||||||||
| B | I | Allogeneic MSCs co-transplanted with haplo-HSCT and DLI | Allogeneic MSCs, no details or dose mentioned | MSC(+): n = 9, MSC(-): n = 17 | NB (relapsed/refractory) | Primary engraftment in 96% (25/26) of the patients | Illhardt et al. [83] | NCT00790413 | 2018 |
| GvHD: no significant differences between MSC and non-MSC group | |||||||||
DLI–donor lymphocyte infusion, haplo-HSCT–haploidentical HSCT, aGvHD–acute graft-versus-host disease.